FDA Drug Trials Snapshots and Diversity When Testing New Drugs By Anna Jurczynska | March 29, 2017 Posted in Recent News and tagged FDA, John J. Whyte, patient populations, U.S. Food and Drug Administration ← FDA Proposes Eight-Month Review of Priority Generics, Plans for Wave of BiosimilarsCAT monthly report of application procedures, guidelines and related documents on advanced therapies →